Podcasts about Chemotherapy

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Watch Delta's heartwarming reunion with her dad at St. Jude go viral, capturing the hearts of millions as she battles leukemia.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My guest is Dr. David Fajgenbaum, MD, professor of translational medicine and human genetics at the University of Pennsylvania. He explains how, unbeknownst to most doctors, many approved medications can successfully treat or even cure diseases other than the ones they are typically used to treat. He shares his story of escaping death from Castleman's disease by discovering a life-saving treatment using repurposed drugs that were approved for other purposes. Our conversation explores how researchers, physicians, and you—the general public—can explore novel treatments and cures to conditions the medical profession has deemed untreatable, including cancers. We also discuss the crucial role of mindset in battling diseases and the lesser-known use of compounds to promote health and longevity. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Eight Sleep: https://eightsleep.com/huberman Rorra: https://rorra.com/huberman David: https://davidprotein.com/huberman Function: https://functionhealth.com/huberman Timestamps (0:00) David Fajgenbaum (4:06) Self-Agency in Healthcare; New Uses for Old Medicines (6:44) Other Uses of Aspirin & Viagra; Drug Development & Approved Use (8:53) Lidocaine & Breast Cancer; Pharmaceutical Companies & Incentives (11:36) Sponsors: Eight Sleep & Rorra (14:16) Pharmaceutical Companies, Patents & New Uses; Lithium (18:40) Tools: Finding Reliable Health Sources, Asking Questions & Disease Organizations; DADA2 Treatment (21:53) Medical Community & Connections; Integrated Medical Databases (24:36) Drug Repurposing, Thalidomide, Pembrolizumab (28:45) Medical Research Databases, Mapping Disease Connections (33:51) Every Cure Database & Programs, Bachmann-Bupp Syndrome; Colchicine & Heart Disease (37:57) Sponsors: AGZ by AG1 & David (40:41) David's Medical & Career Journey, Glioblastoma, Castleman Disease (49:10) Autoimmune Disease, Driven Personality, Stress & Immune System (52:52) Castleman Disease, Treatment, Chemotherapy (55:54) Physician Continuing Education, Santa Claus Theory of Civilization; Science Collaboration (1:03:32) Medical School, Relapse & “Overtime”, Finding a New Treatment, Rapamycin (1:12:46) Sport, Football & Resilience; Challenge & Personal Growth, Family (1:18:41) Sponsor: Function (1:20:29) Social Support; “Overtime”, Gratitude (1:23:19) Business School, Castleman Disease Treatment; Repurposing Drugs & AI (1:28:29) Drug Repurposing, POEMS Syndrome; Mitigating Risk (1:35:32) Nicotine, Compounds for Preventive Health; GLP-1 Agonists (1:40:51) Bioprospecting, Drug Development; AI, Prioritization & Novel Connections (1:46:18) Healthcare & Children; Hope, Action & Impact Circuit; Challenge & Super-Agers (1:52:50) Get Involved with Every Cure (1:56:20) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

Receipt of an mRNA vaccine for Covid within 100 days of beginning immunotherapy for lung cancer or melanoma increased a person's survival likelihood by a factor of two or greater, a new study shows. Johns Hopkins mRNA expert Jeff Coller … Might mRNA vaccines replace chemotherapy for cancer treatment? Elizabeth Tracey reports Read More »

Following a fruitful European Society of Medical Oncology (ESMO) Congress 2025 for gastrointestinal malignancies, CancerNetwork® organized an X Spaces discussion hosted by 3 experts. They were Nicholas J. Hornstein, MD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health; Timothy Brown, MD, an assistant professor in the Department of Internal Medicine and the associate program director of the Hematology & Oncology Fellowship at UT Southwestern Medical Center; and Udhayvir S. Grewal, MD, an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Each doctor focused on a specific disease type, highlighting the most important abstracts in colorectal cancer, pancreatic neuroendocrine tumors (NETs), and upper gastrointestinal cancers. The Phase 3 MATTERHORN Trial (NCT04592913) Results from MATTERHORN demonstrated that adding durvalumab (Imfinzi) to 5-fluorouracil, leucovorin (folinic acid), oxaliplatin, and docetaxel (FLOT) improved overall survival (OS) compared with FLOT plus placebo in patients with resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma, regardless of pathological status.1 In the intention-to-treat population, the median OS was not reached in either arm, and the hazard ratio (HR) was 0.78 (95% CI, 0.63-0.96; P = .021). Notably, the improvement was observed regardless of PD-L1 status; in patients with PD-L1–positive disease, the HR was 0.79 (95% CI, 0.63-0.99), and in patients with PD-L1–negative disease, the HR was 0.79 (95% CI, 0.41-1.50). “This, I believe, will seal durvalumab plus FLOT as the standard of care for resectable [gastric/GEJ] cancers,” said Brown. The Observational ASPEN Study (NCT03084770) The ASPEN study showed that active surveillance was a safe approach for patients with low-grade, asymptomatic, nonfunctioning pancreatic neuroendocrine tumors (NETs) fewer than 2 centimeters in size.2 Of the 1000 patients enrolled in the trial, 20 patients died, of whom 18 underwent active surveillance and 2 underwent surgery. Nineteen of the deaths were unrelated to pancreatic NETs; 1 death in the surgery arm was related to a pancreatic NET. After surgery, 5 patients had disease relapse or progression. With a median follow-up of 42 months (IQR, 25-60), the OS analysis showed a P value of 0.530.  “This really settles the debate on whether or not to surgically operate on patients with a [pancreatic NET] size of [fewer] than 2 centimeters and shows that active surveillance is a safe option for these patients with pancreatic NETs [fewer] than 2 centimeters in size and non-functional NETs,” said Grewal.  Data From the Phase 2/3 FOxTROT (NCT00647530) and Phase 2 NICHE-2 (NCT03026140) Trials Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) achieved a clinically meaningful and statistically significant improvement in long-term outcomes, including responses and survival, compared with chemotherapy strategies in patients with mismatch repair deficient (dMMR) or microsatellite instability–high (MSI-H) locally advanced colon cancer.3 In NICHE-2, neoadjuvant nivolumab plus ipilimumab achieved a 3-year disease-free survival (DFS) rate of 100% compared with 80% (95% CI, 73%-85%) with all chemotherapy strategies in FOxTROT (P

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this week's Principles of New Biology webinar, Tom read Chapter 2 of his developing booklet: “Then Something Happened.” He explores the idea that humanity experienced a profound shift in consciousness beginning in the 1600–1700s—moving from a vitalistic, ether-based understanding of life to a mechanical, reductionist worldview.This chapter dives into:– Lost ancient knowledge and hidden history– Electromagnetism and the four elements– What “the catastrophe” was and how we chose it– Healing with ether, light, and sound– How to reclaim meaning, coherence, and true vitalityThe session also included Q&A on:– Trauma and where it's stored– Sick sinus syndrome and restoring heart rhythm– Antibodies, blood types & Rhesus factor– Vitality, frozen shoulder, and modern vehicles– Chemotherapy recovery, Rife machines & scalar healing– Healing approaches to Crohn's and animal careSupport the showWebsites:https://drtomcowan.com/https://www.drcowansgarden.com/https://newbiologyclinic.com/https://newbiologycurriculum.com/Instagram: @TalkinTurkeywithTomFacebook: https://www.facebook.com/DrTomCowan/Bitchute: https://www.bitchute.com/channel/CivTSuEjw6Qp/YouTube: https://www.youtube.com/channel/UCzxdc2o0Q_XZIPwo07XCrNg

“This was a panel of subject matter experts of various nurses and pharmacists. We often found common ground but also discovered new ideas, different touchpoints, and key junctures along that oral anticancer medication journey. For example, the pharmacists were able to share their insights into their unique workflows within their practice setting. What resulted is a resource that truly reflects that collaborative effort between the disciplines,” ONS member Mary Anderson, BSN, RN, OCN®, senior manager of nursing membership and professional development at the Network for Collaborative Oncology Development and Advancement (NCODA) in Cazenovia, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS. Anderson spoke with Weimer and Kris LeFebvre, DNP, RN, NPD-BC, AOCN®, oncology clinical specialist at ONS, about the Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation, a project created as a collaboration between ONS and NCODA. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD contact hours. ONS Podcast™ episodes: Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice articles: As Institutions Establish Oral Agent Workflows, Savvy Educators Help Nurses Apply Them to Practice Maintain Oral Adherence With ONS Guidelines™ The Oncology Nurse's Role in Oral Anticancer Therapies ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC®Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Implementation of an Oral Antineoplastic Therapy Program: Results From a Pilot Project Oncology Nursing Forum articles: Domains of Structured Oral Anticancer Medication Programs: A Scoping Review Interventions to Support Adherence to Oral Anticancer Medications: Systematic Review and Meta-Analysis ONS Guidelines™ to Support Patient Adherence to Oral Anticancer Medications Other ONS resources: ASCO/ONS Antineoplastic Therapy Administration Safety Standards Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library Drugs@FDA Hematology/Oncology Pharmacy Association Oral Chemotherapy Collaborative National Comprehensive Cancer Network homepage NCODA homepage Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode LeFebvre: “There are five different elements to the care compass itself. The first is called the OAM [oral anticancer medication] workflow analysis tool. ... This [tool] allows an OAM program to really study where their processes are. Where are the gaps in the process and where might their patients be at risk? It's something that you can use within your setting to analyze your current processes and see where you can strengthen them. The second tool is something focused on patient and caregiver education. This includes a lot of information about what should be taught, how it could be taught, the best timing and so forth, according to the literature. ... The third tool is an assessment and grading tool. It's a fun tool that approaches symptom management using the Common Terminology Criteria for Adverse Events grading tool. ... The fourth tool is a specialty pharmacy and patient assistance contact directory template. This is a spreadsheet that can be used by anyone navigating patient care with OAMs to keep track of their professional contacts. ... The final [tool] is the OAM adherence blueprint. This has a lot of important information on adherence, methods to assess adherence, and calculate adherence rate.” TS 7:15 LeFebvre: “Interprofessional collaboration is so essential just in day-to-day care, and OAM care is no different in that regard. Oncology nurses work in so many different settings and their role may be very different even if they have the same title. You can have OAM navigation that is completely handled in the pharmacy. I've talked with nurses who have said, ‘We don't even touch it.' But they do. Because when a patient has a combination regimen, they might have an infusion regimen that goes along with an oral therapy. Or that patient might just know that infusion room nurse so much better and they feel more comfortable [contacting them] when they have a side effect from their oral therapy. So, infusion nurses need to be aware of what the patients are on and what the potential side effects are.” TS 14:14 Anderson: “The resource for OAM education that we created is literally a blueprint of many resources out there to help nurses, pharmacists, and oncology professionals educate their patients on taking OAMs. ... [The OAM Care Compass] also helps with communication channels. It helps knowing that all the documentation is occurring and when everybody is documenting within their role and according to those key touchpoints, there's less opportunity to lose track of your patients because we know what's happening.” TS 16:33 Anderson: “I think the biggest misconception we see is that people think taking OAMs is easier than infusion therapies. And while it's true that OAMs do offer significant benefits such as the convenience and the ability for patients to take their medication at home, we are also placing a huge burden on our patients. They need to navigate that very complex health system to obtain their medication and understand their treatment plan and adhere to that precise regimen. Additionally, we are seeing more and more complex treatment regimens with combination therapies, which further increases the need for that early and ongoing education, monitoring, and support.” TS 20:38

James McConchie is the Founder of Haight Street Shroom Shoppe and started cultivating mushrooms years ago to provide access for his wife as she underwent Chemotherapy - today, he stands as one of the most respected and venerable mushroom entrepreneurs in the San Francisco area and beyond. He joins us today to share lessons from 5 years of running the Haight Street Shroom Shoppe, mushroom culture in California's Bay Area and beyond, and his recent research and development into microdosing for dogs alongside Doc Rob silver of Real MushroomsPlease rate and review this episode wherever you're listening ( : Hosted on Acast. See acast.com/privacy for more information.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

- Non-Small Cell Lung Cancer (NSCLC) Treatment - Current Standard of Care - The Role of Chemotherapy, Radiation Oncology & Targeted Cancer Therapies - New Treatment Approaches - The Role of Biomarkers & Precision Medicine in Informing Treatment Choices - How Clinical Trials Contribute to Treatment Options - New Ways to Manage Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Key Questions to Ask When Communicating with Your Health Care Team - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - The Important Role of Lifestyle & Movement - Questions for Our Panel of Experts

- Non-Small Cell Lung Cancer (NSCLC) Treatment - Current Standard of Care - The Role of Chemotherapy, Radiation Oncology & Targeted Cancer Therapies - New Treatment Approaches - The Role of Biomarkers & Precision Medicine in Informing Treatment Choices - How Clinical Trials Contribute to Treatment Options - New Ways to Manage Treatment Side Effects, Symptoms, Discomfort & Pain - Communicating with Your Health Care Team About Quality-of-Life Concerns - Nutrition & Hydration Concerns & Tips - Key Questions to Ask When Communicating with Your Health Care Team - The Increasing Role of Telehealth/Telemedicine Appointments - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - The Important Role of Lifestyle & Movement - Questions for Our Panel of Experts

Title of Account: Shaukat Khanum Memorial Trust* | -For Donation Account: Bank ALfalah: 00311000012854Babar Shaikh, the husband of Zahra Khan, joins us for a heartfelt conversation around Breast Cancer, losing loved ones, therapy and finding the will to go on.The Pakistan Experience is an independently produced podcast looking to tell stories about Pakistan through conversations. Please consider supporting us on Patreon:https://www.patreon.com/thepakistanexperienceTo support the channel:Jazzcash/Easypaisa - 0325 -2982912Patreon.com/thepakistanexperienceAnd Please stay in touch:https://twitter.com/ThePakistanExp1https://www.facebook.com/thepakistanexperiencehttps://instagram.com/thepakistanexpeperienceThe podcast is hosted by comedian and writer, Shehzad Ghias Shaikh. Shehzad is a Fulbright scholar with a Masters in Theatre from Brooklyn College. He is also one of the foremost Stand-up comedians in Pakistan and frequently writes for numerous publications. Instagram.com/shehzadghiasshaikhFacebook.com/Shehzadghias/Twitter.com/shehzad89Join this channel to get access to perks:https://www.youtube.com/channel/UC44l9XMwecN5nSgIF2Dvivg/joinChapters:0:00 introduction2:00 Babar and Zahra's love story14:20 The diagnosis and Breast Cancer awareness21:00 Treatment, Chemotherapy and Relapse30:30 Marriage, Support and the taboo of Breast Cancer38:00 Mental Health and trying to be normal45:00 Non traditional treatments, health and diet1:02:30 Anxiety, Faith and Therapy1:08:30 Awareness and finding the strength to go on

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Out of the Fire podcast, host Trisha speaks with Lynn Whitt, an inspiring 83-year-old ovarian cancer survivor who has battled the disease since her diagnosis at age 67. Lynn shares her journey through 150 rounds of chemotherapy, the challenges she faced, and the importance of finding motivation to keep fighting. The conversation highlights the role of compassion in healthcare, the significance of support systems, and the advancements in cancer treatment that have made a difference in patients' lives. Lynn's story serves as a beacon of hope and resilience for anyone facing similar struggles. Chapters 00:00 The Diagnosis Journey 06:47 The Role of Family and Support 11:43 Lessons Learned and Advice for Others 16:37 Hope and Technological Advances in Treatment 21:54 Finding Your Why in Difficult Times 23:13 The Importance of Support and Resources www.trishafraley.com www.madetowalkthroughfire.com

Chemotherapy, radiation, childbirth, menopause, etc. can all throw off the delicate balance of your vaginal microbiome. And yet, many women (and even doctors) don't know much about how to restore and care for their vaginal health.  And since breast cancer healing requires a complete, full-body transformation, we took matters into our own hands and interviewed trailblazers Wendy Strgar, a woman who has revolutionized vaginal health with technology, science, and empathy. As the founder of Good Clean Love, Vaginal Biome Science, and Womankind Care, Wendy has spent decades pioneering non-toxic, biomimicry-based solutions that restore the delicate balance of the vaginal microbiome…even after cancer treatments. She created her patented Bio-Matched® technology and developed the first microbiota testing panel focused on vaginal health. If you've ever struggled with vaginal discomfort, odor, or recurring infections, and felt like your providers just “don't get it,” this conversation is for you.  To try her products for yourself, use our exclusive code “WELLNESSWARRIOR20” at GoodCleanLove.com. It also pairs well with our Estro-Clear supplement as discussed in the episode.

Jeff Glazier, CEO of General Oncology, is taking a unique approach to treating cancer by using older chemotherapy drugs with broad action but in novel combinations designed to avoid the incidental toxicity.  Their primary drug in trials is GO-4 which is focused on shutting down DNA repair in cancer cells to overcome drug resistance.  While testing in patients with stage 4 pancreatic cancer, this approach was designed to combat tumor heterogeneity by targeting fundamental processes like proliferation that are common to all cancer cells within a tumor. Jeff explains, "We're actually taking a different approach than a lot of companies are. And I would say there are really two approaches because we have two different things on, we have a clinical trial right now where we're using old chemotherapy drugs in a new way, and when you combine them together, you really get just a different result. We're trying to shut down DNA repair and kill cancer cells. But the other really interesting thing, and I think it's underlying general vision, is chemotherapy drugs long ago had very broad action, and with broad action comes unwanted incidental toxicity. And over the years, it's been huge in the industry, or moving towards specific drugs that target specific things and have less incidental toxicity. The unfortunate side effect is that cancer cells can evolve around a drug if there's too much specificity. So we're taking a pretty novel approach with our business of going after drugs that have broad action, but we found a way, we believe, to do it in a way that doesn't have incidental toxicity." "I certainly feel that you want to have more than one attack. If you only do one, the cancer cells can evolve around it. The drug resistance approach I was referring to was what we call GO-4 in our clinical trial, and we're altering part of the cancer cells' fundamental biology that is involved in DNA repair and shutting it down. But we're doing it in more than one way."   #GeneralOncology #PancreaticCancer #CancerAwareness #MetastaticCancer #GO4Therapy #CancerResearch #InnovativeTherapies #DrugDevelopment generaloncology.com Download the transcript here

Jeff Glazier, CEO of General Oncology, is taking a unique approach to treating cancer by using older chemotherapy drugs with broad action but in novel combinations designed to avoid the incidental toxicity.  Their primary drug in trials is GO-4 which is focused on shutting down DNA repair in cancer cells to overcome drug resistance.  While testing in patients with stage 4 pancreatic cancer, this approach was designed to combat tumor heterogeneity by targeting fundamental processes like proliferation that are common to all cancer cells within a tumor. Jeff explains, "We're actually taking a different approach than a lot of companies are. And I would say there are really two approaches because we have two different things on, we have a clinical trial right now where we're using old chemotherapy drugs in a new way, and when you combine them together, you really get just a different result. We're trying to shut down DNA repair and kill cancer cells. But the other really interesting thing, and I think it's underlying general vision, is chemotherapy drugs long ago had very broad action, and with broad action comes unwanted incidental toxicity. And over the years, it's been huge in the industry, or moving towards specific drugs that target specific things and have less incidental toxicity. The unfortunate side effect is that cancer cells can evolve around a drug if there's too much specificity. So we're taking a pretty novel approach with our business of going after drugs that have broad action, but we found a way, we believe, to do it in a way that doesn't have incidental toxicity." "I certainly feel that you want to have more than one attack. If you only do one, the cancer cells can evolve around it. The drug resistance approach I was referring to was what we call GO-4 in our clinical trial, and we're altering part of the cancer cells' fundamental biology that is involved in DNA repair and shutting it down. But we're doing it in more than one way."   #GeneralOncology #PancreaticCancer #CancerAwareness #MetastaticCancer #GO4Therapy #CancerResearch #InnovativeTherapies #DrugDevelopment generaloncology.com  Listen to the podcast here

“Chemotherapy-induced alopecia does cause a lot of stress. It's associated with lower quality of life. Scalp cooling may really help improve quality of life. Some studies have shown that women in the scalp cooling group felt less upset about losing their hair and less dissatisfied with their appearance compared to the women in the control group that didn't receive any scalp cooling. So a lot of these studies are showing it does have a very positive impact on psychosocial feelings and side effects in relation to overall cancer treatment,” ONS member Jaclyn Andronico, MSN, CNS, OCN®, AOCNS®, clinical nurse specialist at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about chemotherapy-induced alopecia and scalp cooling. The advertising messages in this episode are paid for by Paxman. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ Episode 250: Cancer Symptom Management Basics: Dermatologic Complications ONS Voice articles: Diagnose and Manage Dermatologic Toxicity Secondary to Immunotherapy Follow the Evidence When Using Scalp Cooling for Cancer Alopecia Reimbursements Are Making Scalp Cooling More Accessible for Patients With Cancer The Case of the CIA-Combatting Combination ONS Voice oncology drug reference sheets: Docetaxel Doxorubicin Hydrochloride Sacituzumab Govitecan-Hziy ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity Clinical Journal of Oncology Nursing articles: Chemotherapy-Induced Alopecia: Examining Patient Perceptions and Adherence to Home Haircare Recommendations Scalp Cooling: Implementing a Cold Cap Program at a Community Breast Health Center Scalp Cooling: Implementation of a Program at a Multisite Organization Oncology Nursing Forum articles: Effectiveness, Safety, and Tolerance of Scalp Cooling for Chemotherapy-Induced Alopecia The Effect of Chemotherapy-Induced Alopecia on Distress and Quality of Life in Male Patients With Cancer ONS Altered Body Image Huddle Card Journal of Market Access and Health Policy article: Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia HairToStay Paxman patient assistance program Rapunzel Project To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Some of the classes that are high risk for chemotherapy-induced alopecia can include antitumor antibiotics, such as doxorubicin, epirubicin; antimicrotubule drugs, such as taxanes like docetaxel, paclitaxel; alkylating agents such as cyclophosphamide. The lower risk alopecia-causing chemo agents are the antimetabolite classes, which a lot of people know as gemcitabine or fluorouracil. We also are seeing patients experience some degree of alopecia with a drug called sacituzumab govitecan, which is an actual antibody–drug conjugate.” TS 2:09 “Scalp cooling is approved for solid tumor patients. Patients receiving chemotherapy agents, as we discussed before, with that high incidence of chemotherapy-induced alopecia really should be considered for scalp cooling as long as they don't have certain contraindications. Some contraindications do exist for these populations. Those are patients that have cold agglutinin diseases, cryoglobulinemia, cryofibrinogenemia, and any cold sensitivity issues. Patients also with abnormal liver functions are not suggested to receive scalp cooling because their liver function is associated with the metabolism of the drug agent. It's also not recommended for patients with hematologic malignancies who are higher risk for cutaneous metastatic disease or failed chemotherapy and even reduced survival rates.” TS 9:23 “Overall, scalp cooling has a good tolerance, but it's important to be aware that scalp cooling can be uncomfortable for some, and it isn't always tolerated by some patients. Patients have reported side effects such as headaches, dizziness, chills, cold sensations, scalp pain, head discomfort, and even claustrophobia. Among these, the most common is the cold feeling and headaches. So when caring for patients that undergo scalp cooling, the nurses really should recognize the patient's feelings and help relieve that discomfort with position changes, prophylactic painkillers such as [acetaminophen] or [ibuprofen] if they're allowed to take that, additional warm blankets. Even antianxiety medications can really help, especially if that claustrophobia feeling is there. So collaborating with that team, the doctors, the nurse practitioners, just to be aware that if the patient's not comfortable during this treatment of scalp cooling, they should have those things on board prior to starting.” TS 12:23 “A lot of primary education points for nurses to review with patients is explaining the financial reimbursement process and assistance options—collaborating with that financial department within your institution. Also discussing the efficacy of the scalp cooling and the tolerability of it as well. I don't know if patients are always aware of the feeling of the cold—really warning them, letting them know what they're going to experience while in the chair attached to that cooling machine.” TS 18:55 “Nurses, we're at the forefront of scalp cooling, and we manage a lot of this area that comes with the service. They are managing, the coordination of the care, the education. They're assisting with that financial discussion and collaborating with the financial department. The symptom management—they're helping make the patients feel more comfortable with the symptoms of scalp cooling. They are the real deal here, so they are the best in helping with the situation. Nurses should be really familiar with the efficacy, again, and the tolerability, the contraindications, the side effects, and the costs and even the access for scalp cooling.” TS 20:57

Listen to JCO's Art of Oncology article, "A Fight Bigger Than Myeloma” by Dr. Adeel Khan, an Assistant Professor of Medicine and Public Health at UT Southwestern. The article is followed by an interview with Dr. Adeel Khan and host Dr. Mikkael Sekeres. Dr. Khan shares the story of a patient whose multiple myeloma diagnosis and treatment serves as a reminder of the civil liberties progress we've made and that we have more to go. TRANSCRIPT Narrator: A Fighter Bigger Than Myeloma, by Adeel M. Khan, MD, MPH, MS  I met her during the early part of my clinical training in hematology/oncology. She was in her late 70s, dressed in a rust-colored cardigan and a headwrap with patterns that reminded me of Ghanaian kente cloth. Her eyes were sharp, her tone polite but direct. You could tell from the moment she spoke that she had lived a life where she had to advocate—for herself, for her family, for her place in rooms that were not always welcoming.  Her chart said “multiple myeloma, R-ISS II,” but it did not say that she had first come to an emergency room at least a year earlier complaining of back pain and fatigue and had been told it was probably arthritis or old age. It did not mention that she had seen three different doctors before someone ordered the laboratory tests that finally began to work up her anemia and increasingly compromised kidney function. It would take another trio of doctors to eventually order a magnetic resonance imaging whose ghostly lytic lesions led down the path to a bone marrow biopsy and her cancer diagnosis. When I brought this up gently during one of our early appointments, she looked at me and said, “They don't hear pain the same when it comes from someone like me.” As a Black woman from the Deep South, she had grown up learning how to navigate a health care system that did not always believe her. She told me stories about being dismissed, misdiagnosed, and interrupted. She was born into an era of structural violence where she would be ignored at best and mistreated at worst. She carried the weight of those moments, but she also carried strength, and clarity, and the kind of dignity that made people sit up straighter in their leather chairs when she entered the room. She was one of the most quietly revolutionary people I have ever known, having grown up during a time of civil rights activism. She had even taken part in bending Dr King's long arc of the moral universe toward justice and could share story upon story from her glory days. Her myeloma treatments were not easy. Chemotherapy rarely is. She shared that there were days when her body was tired of fighting, when her bones ached, her blood counts dropped, and her neuropathic pain throbbed. In the back of my mind, I thought how tragic it was that her delayed diagnosis added unnecessary complications and whether she too thought of that. She was fully mindful of the issues people with her skin color faced in our American healthcare system and society as a whole and revealed how that motivated her to carry forward. “If I don't take up space here,” she told me once, “then someone else like me won't either.” Over the course of our visits, I came to understand that she did not see her myeloma as the hardest fight of her life. Not by a long shot. Her primary struggle was centered on life in Birmingham in the 1950s where separate but equal was still the law of the land; her mother cleaned houses, her father worked odd jobs, and her own prospects were uncertain. She admired the writings of Richard Wright and Jean Toomer and was not shy in sharing her passions. One day, during a particularly tough visit—her disease had progressed and we were down to limited options—I found myself meandering. We went through the usual workup and discussions: laboratory test results, symptoms, and treatment options. I offered the prospect of clinical trials, but she shook her head gently and said, “I've done my time in experiments—I can't give myself to a system that gave my people so little.” I paused. It was the first hint of what would become a larger conversation—not just about medicine, but about history. She was well aware of the atrocities of the Tuskegee syphilis trials in her home state, the Kligman experiments on incarcerated Black men, and the forced sterilization of women of color. As dependent upon medicine as she was in her old age, it carried a bloody stain of dehumanizing racism that soured her against it. Outwardly, I had little in common with her. As a young South Asian man growing up in times more conscious of racial injustice, I was far removed from these historical crimes. Although I learned of them during my education, I did not internalize their impact on the patients in front of me in clinic. But through her I came to comprehend just how scarring and enduring these events can be and how they can rob someone of trust. And the truth is the health care system had not treated her well. She had personal stories of doctors who did not believe her pain, nurses who assumed she was uneducated,  and being passed over for better options, better care, and better answers. “But I kept showing up,” she said. “Because that's what we do. We show up even when we're not wanted.” Her stories to me were revelations. In her younger years, she had helped organize teachers at her school when they tried to fire a fellow Black teacher who seemingly spoke too loud in a meeting. She had lived through redlining, through the crack epidemic, through watching young Black men vanish into prisons, and still she rose every day and worked as a public school teacher for decades. She worked for a system that largely did not work for her. I came to admire that about her—that in simply living day-to-day life with plain dignity and acute awareness of society's issues, she promoted change by living it. “You want to talk about cancer?” she once said, half laughing. “Try walking into a bank in 1972 with a good credit score and a Black face. That's a disease this country still hasn't cured.” Curiously, she did not say these things with bitterness. Not even anger, really. Just clarity. Like someone who had long ago made peace with the truth, even if it was sharp. In clinic, she challenged my every assumption—about treatment tolerance, about compliance, about who is difficult, and who is “advocating.” And she taught me to look differently at the ways bias lingers in medicine. Not just in data or policies, but in subtle moments: the tone we use when explaining options, the hesitations in our tests and referrals, and the assumptions we may not even realize we are making. And she did not just expect good care—she demanded it. She told me early on, “Don't you treat me like I'm anything other than your mother.” That landed. And in seeing patients before me now, I remind myself to wonder who they were in their past lives, what baggage burdens them, and how it all shapes their perspectives. So from my view, she fought multiple myeloma with everything she had, but from hers, she fought something bigger: an entire system shaped by inequality. And ultimately, she made me better to realize that, not just as a doctor, but as a human being. In my years since knowing her, completing my training, and beginning my practice, I reflect on her grace. I think not just about her life, but what it means to practice medicine in a world that often forgets what patients carry with them into the clinic—generations of weight, of injustice, of strength. Mikkael Sekeres: Welcome back to JCO's Cancer Stories, The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. I am so happy that today we are joined by Adeel Khan, who's Assistant Professor of Medicine and Public Health at UT Southwestern in Dallas to talk about his Journal of Clinical Oncology article, “A Fight Bigger than Myeloma.” Our guest's disclosures will be linked in the transcript. Adeel, thank you so much for contributing to JCO and for joining us to discuss your article. Adeel Khan: Thank you so much for having me. It's a pleasure to be here. Mikkael Sekeres: Adeel, I don't want to be disingenuous to our readers by acting as if we've just met. You and I have known each other for a decade since you were still in your training. I wonder if for our listeners you can tell us a little bit about yourself, where are you from and and walk us through your career so far. Adeel Khan: More than happy to. So, I grew up mostly in Oklahoma, but I've sort of lived around in the Northeast and here in the Southwest where I am currently. I did college at the University of Oklahoma. I did medical school at the University of Michigan. I did residency with good fortune at the Cleveland Clinic where I happened to get to know you and have continued to know you since. I did my fellowship then in hematology oncology at Beth Israel Deaconess in the Harvard system and along the way of all that I did a Masters of Public Health at Harvard and a Masters of Science and Epidemiology at Columbia, and that pinball finally settled here to UT Southwestern here in Dallas which I am very happy to make my second home. Mikkael Sekeres: That's great. I will say just for our listeners you've been a superstar since the moment you were a resident. It's been a real treat for me to get to know you over the years. Adeel Khan: Thank you so much. Mikkael Sekeres: Can you tell us a little bit about your own story as a writer? You're a good writer. We get submissions from some really good writers every single week. It's a real privilege to be an editor for the Art of Oncology section and it's always reinvigorating to me to see how many good writers there are in medicine. How did you start your journey as a writer and how long have you been writing reflective narrative pieces? Adeel Khan: I would say if I went back to let's say high school, you know, people tend to be divided into kind of like the sciency types versus the literary arts types and you're kind of an either/or, you know, you didn't really have as much crossover then. But you know, I actually didn't mind when we had an essay due and I liked writing back then, and when I entered college I did a minor in English because I actually did enjoy that and I just liked the idea of being able to put your thoughts on paper in a way immortalizing them. Adeel Khan: And then as I sort of pursuing medicine more and more, publishing is really- it has all kinds of flavors to it and scientific publishing is obviously what has been emphasized, but you know, there's so many things to talk about within medicine. There's the science and the art of the field, and as I've moved along, I've written different pieces focusing really on patient stories and interactions. And I think my motivation has always been that as I have gotten particularly nowadays increasingly busy, I've had the fortune and misfortune of becoming more and more busy, it's easy to lose the opportunity to really connect with people that makes what we do meaningful. And so in those times when you know, and they can be rare, but when you really get to connect with someone in front of you who you're helping to care for, it's really refreshing and it's rejuvenating and I've tried to keep that with me as long as I can as I've gone through my journey. Mikkael Sekeres: There's a lot of jumping off points from what you just said, Adeel. I wonder if I can start with do you consider yourself an English major who's good at science or do you consider yourself a scientist who's a good writer? Adeel Khan: I think I'm too humble to say either. I think I was really a science major who just happened to like writing and reading and kept that as a part of myself. Mikkael Sekeres: Because I think there are a cadre of doctors who are actually English majors and have learned to turn science into storytelling and that's their entrée into science and medicine. I remember I talked for a while with David Scadden about this. He's a brilliant translational scientist who's based at Mass General who also teaches a writing course to the Harvard undergrads and who was an English major when he was an undergrad at Case Western. We've talked about this, about how there are people, I'll include myself in this, who just think different, who probably have these liberal arts brains and they figured out a way to convert science into a way a liberal arts person can understand it. Adeel Khan: Yeah, I mean narrative medicine has been I think around all along and it has only kind of been recently named as a field, but I mean it very much speaks to that that there's so much more than just G proteins in medicine. Mikkael Sekeres: I'm thrilled to hear that by the way. You mentioned you were an English minor. Are there particular writers who are an influence on you or can you talk about what's the most recent book or article you've read? Adeel Khan: Oh, that is a great question. Paulo Coelho is someone I've liked for a long time, The Alchemist. I really liked it because I read it after I had lived in Egypt. I lived in Egypt between college and med school as a study abroad program, and I had actually been to the Faiyum Oasis where the protagonist in that story ends up. And so it was just a fascinating story to me that I could trace some of the steps that are discussed in the book and it's so much- it's a story about self discovery which at that phase of life that I was in was you know, very much a theme of my own life. And so that's one that definitely stands out in my head. Mikkael Sekeres: Do you think reading pieces outside of medicine makes you a better scientist? Adeel Khan: I think absolutely. I think it makes you a better human being. In some ways I lament that so much of what I do reading now is so much just about what's in the field, what's new in myeloma, what's new in hematology oncology and I sort of miss the escape to reading other things and being able to pursue it. And even broader than just what a novel really offers. I mean, I grew up reading comic books too and I've always loved superheroes and fiction whether it's Star Wars and other things. And really they're just stories and the medium- there might be connotations whether it's a comic book or a or a novel, but they're just different mediums, but the fact that they're just stories is fundamental. I actually think to myself that it's so fascinating that the earliest piece of writing that we've really retained as human beings is we believe, the Epic of Gilgamesh, which is really a story of a superhero when you think about it, you know, and it's it's fiction, it's phantasmic in so many ways. But it speaks to how stories are just vital as people. Mikkael Sekeres: And what is it about graphic novels or my kids now of course call them graphic novels. We're not allowed to call them comic books. Adeel Khan: As they've been renamed, yeah. Mikkael Sekeres: What is it about graphic novels or comic books or the story of a hero that appeals to us in medicine? Adeel Khan: I think it's in some ways a parable of what we're doing. There's something so powerful and fundamental about this idea of good-evil and we can rename it in different ways, but that you're trying to overcome something that's an issue, an obstacle. And when you think about what we do in- particularly in oncology, that's very much what we're trying to do. We're trying to overcome an illness, a disease, to try to help the person in front of us. And it has different aspects to it. It could be someone pursuing something in a lab, it can be treating someone in front of you in clinic, but that simple dichotomy of there's something good about what you're doing because there's something bad in front of you is just the fundamental that runs through it all. Mikkael Sekeres: It's fascinating. I wonder if 30, 40, 50 years ago people would have said, “Oh, it's because the doctor is the hero,” but we don't view ourselves that way anymore. The patient is the hero. I love how you posit this as a good versus evil, the evil of course being cancer and the good everything that our patients do and that we try to to help to do to overcome that. Adeel Khan: For sure. Mikkael Sekeres: You wrote a really great essay about a woman who was a patient of yours. Can you tell me a little bit about what inspired you this time to make this connection and to write about this woman? Adeel Khan: Within the past year or so as I had been just really- the fortune and misfortune of getting busier, I lamented that I just wasn't able to spend as much time with patients in the way that I used to. One of the beauties of medical school and you know, to some degree residency and certainly fellowship is that you just have a little bit more time as a trainee, student and trainee where you can really bond with your patients I think a little bit more. And so in trying to kind of refresh my motivation, I was thinking about just kind of randomly some stories that I've kept in the back of my mind and this patient's story is one that stood out to me as I was recalling things. It was so fascinating to me because she had the disease which I now focus on. And the way that she viewed it and the way that she viewed it as a part of her life was just so different than what I think most people think of. And in that way it was very revitalizing that her focus in her life was part of a broader theme of the way that I think she viewed society. And this was just one piece of her own part of that much, much larger puzzle. Mikkael Sekeres: You really write lovingly about her and about how meaningful her context was in how you cared for her and what her experience was in the medical system. I wonder if I can read a little bit of what you wrote because it really did grab me as well. I'm going to start out by quoting you where you say, “Outwardly, I had little in common with her. As a young South Asian man growing up in times more conscious of racial injustice, I was far removed from these historical crimes. Though I learned of them during my education, I did not internalize their impact on the patients in front of me in clinic. But through her, I came to comprehend just how scarring and enduring these events can be and how they can rob someone of trust.” Wow, there's a lot there. Could you start with what was your perspective as a young South Asian man growing up in Oklahoma and what your view was of racial injustice compared to what her experience was of racial injustice? Adeel Khan: Yeah, I have to admit I don't know that I thought that much of it back then and I think that that's part of what it is. You know, being someone who was South Asian, I'm Pakistani, I have Indian roots, and coming into American history and as we learned about it there's so much about slavery and the theme of slavery unfortunately and and the struggles that enslaved peoples have. And you know, as a relatively recent immigrant, I didn't see myself in that narrative. I didn't see myself in that historical reality. But I knew about it intellectually, you know, I knew about the Tuskegee Syphilis Experiments, you know, I learned about all these things and and you learned about how atrocious so much of it is. But again, not being so directly connected, I did not put myself in that same role as someone to view it so close to myself. I will say it hit a little bit more after 9/11 when you know, I was randomly stopped at airport security a little bit more often in those days and again, I think that speaks to racial injustices, you know, I was certainly profiled looking back then, I've been held by TSA in the past, but even that is very minor compared to what African Americans have dealt with here. And this patient in just kind of sharing her tidbits during our time together, I was not directly asking her so much of this. She was really offering a lot of it to me as we would talk and she would be very generous in sharing parts of her story. And over time I kind of understood the broader narrative of her life. You know, it was clear how much of all that was actually in the forefront of her head. Adeel Khan: And I think she might have been a little bit more unique in the way that she kept it there, but she was hyper vigilant of issues of society and the roots that brought a given society to where it is here. I kind of got to know her, this is during the COVID pandemic and this was after the injustice of what happened to George Floyd and so it was a theme that I think people were talking about more and so I think she felt comfortable in saying really what was quite a bit that was stewing in the back of her head seemingly at all times. Mikkael Sekeres: It's so interesting you talk about what you endured after 9/11 as being, I'm going to quote you now, “minor” compared to what she's been through, but even a minor affront like that can really compromise your trust. You write about her, “As a Black woman from the deep South, she had grown up learning how to navigate a healthcare system that did not always believe her.” Can you expand on that a little bit? How is it that the healthcare system didn't believe her and what can we do going into interactions with patients from different backgrounds where we're incorporating that there's a compromise of trust and we have to make up for that? Adeel Khan: Yeah, and I think you know, it's so unfortunate that so many people have stories like this where, in her case really it was back pain that was her presenting symptom. This is long before she knew me. And she'd had the back pain for quite some time, but being an older woman, she was in her 70s at that time, she was not in phenomenal health for other reasons. It sounds like she was just kind of ignored, told that it was old age, tendon changes, she did not have meaningful imaging for some time. When she finally did after seeing a slew of different providers, that's when it was revealed like there's something more significant here. And then when you kind of piece that a little bit retrospectively and I think she certainly sensed this and I did when I- hindsight's always 20/20, when I looked through things, it's like, well, this probably could have been caught much earlier. It's just that no one really I think listened to what she was speaking to with her pain and the gravity that was actually behind it. And it just speaks to the fact that I think we have to be more thoughtful in what we take away from patients and not to ignore even small comments because they might be revealing of something much bigger behind them. Mikkael Sekeres: You quote her, you have some really great quotes in your essay where you just listen to what she says and transcribe it because what she says is very meaningful. And one of the quotes you provide from her is, “They don't hear pain the same when it comes from someone like me.” Wow. “When it comes from someone like me,” someone like her, how was it that people weren't hearing her description of pain, something that was different that was going on in her body and how can we be more attentive to people when they complain about things like pain? Adeel Khan: It's unfortunate that there's even known data to show how depending upon a patient's melanin content in their skin, how likely they are to get pain medications and what happens to them is different and this is an unfortunate example of that where I think she just wasn't heard properly. And so it wasn't addressed properly and she was not shy about saying that. I mean I think she sensed that. She was very clear in feeling that herself and in wanting to have better care, she was still prevented and hence why she had to go from provider to provider. Mikkael Sekeres: You've lived in a bunch of different places in the country. I mean, following your path, you've been in Oklahoma, you've been in Michigan, Ohio, Massachusetts, and now Texas. Do you think that we as providers have to have different levels of sensitivity depending on where in the country we're practicing and how some of our patients' trust in healthcare may have been compromised in those different parts of the country? Adeel Khan: I think absolutely. I mean this particular patient was from Alabama which has a heavy history that she was again very aware of and for those of us reading history books are also very aware of too. And it's interesting how, while the U.S. is in some ways- has some aspects that are monolithic, but it's very much not so. It's very patchy and people are different, you know, if I take one theme that we're talking about here is obviously racial injustice, but if you take something like obesity, you know, prevalence rates are very different throughout the country and attitudes surrounding it are also very different. And I think we do- ought to be mindful that in treating the patient in front of us, it's not done without context. And so how they view their illness and their situation is going to be different depending upon the state, depending upon the city, depending upon actually even the era that they grew up in. So I would say now, if you took actually a similar patient, but you put her in a very modern context post-year 2000, she's likely to have different feelings of the situation around her than someone who was born in this case in the 1940s. And that just speaks to the fact that circumstances change and we should be recognizing that as providers, even though it's not always easy to. Mikkael Sekeres: Well, it just emphasizes how very important it is to know the history of the place where we practice and how it's affected our patients' perceptions of healthcare and trust and being cared for, particularly now as there's such a movement to whitewash that history and eliminate it from major institutions like the Smithsonian. It has been such a pleasure to have Adeel Khan here. He is Assistant Professor of Medicine, Public Health at UT Southwestern in Dallas and wrote just a great JCO article called “A Fight Bigger Than Myeloma.” Adeel, thank you so much for submitting your article and for joining us today. Dr. Adeel Khan: Thank you so much for having me. It's been a pleasure. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen and explore more from ASCO at ASCO.org/podcasts. Until next time, this has been Mikkael Sekeres for JCO Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Show Notes Like, share and subscribe so you never miss an episode and leave a rating or review.  Guest Bio: Dr Adeel Khan is an Assistant Professor of Medicine and Public Health at UT Southwestern.

(Animated Stories Podcast Video Podcadt link

In this Episode, Radiation Oncologist, Dr. Stephen Kpatsi helps us understand systemic and localized treatment approaches to cancer through chemotherapy and radiation therapy, their mechanisms of action, side effects, and how they complement other treatment modalities.

For the first time ever, the U.K. has appointed a woman as the Archbishop of Canterbury to lead the global Anglican Communion. Kaitlyn, Skye, and Mike Erre discuss the implications of appointment and how Anglicans use “flying bishops” to maintain unity over divisive theological issues. Are there lessons here for other divided Christian communities? The latest “State of Theology” report shows a shocking number of evangelicals hold contradictory beliefs. Why are evangelical churches so bad at teaching the Bible and theology? Kaitlyn talks with A.J. Swoboda and Nijay Gupta, co-authors of “Slow Theology,” about how our cultural addiction to speed and quick answers actually fuels spiritual disillusionment and deconstruction. Also this week—new data shows why most female animals outlive males. Holy Post Plus: Ad-Free Version of this Episode: https://www.patreon.com/posts/140691242/   0:00 - Show Starts   3:08 - Theme Song   3:30 - Sponsor - Blueland - Get up to 15% off your first order by going to https://www.Blueland.com/HOLYPOST   4:40 - Sponsor - AG1 - Get the AG1 welcome pack when you order from https://www.drinkag1.com/HOLYPOST   6:11 - Men Die Sooner Than Women!   14:22 - Women Can Be Archbishops?   36:15 - Why Don't Evangelicals Know Theology?   52:49 - Sponsor - BetterHelp - This episode is sponsored by BetterHelp. Give online therapy a try at https://www.betterhelp.com/HOLYPOST and get 10% off your first month!   53:50 - Sponsor - Sundays Dog Food - Get 40% off your first order of Sundays. Go to https://www.SundaysForDogs.com/HOLYPOST or use code HOLYPOST at checkout.   55:55 - Interview   56:17 - Why Slow Theology?   59:50 - Deconstruction as Chemotherapy   1:13:17 - Orthodoxy for Power Rather Than Obedience   1:27:02 - End Credits   Links Mentioned in News Segment: Why Women Live Longer: https://www.mpg.de/25470066/0926-evan-why-women-live-longer-than-men-150495-x   Anglican Church Tension Over Woman as New Archbishop: https://www.christianitytoday.com/2025/10/archbishop-of-canterbury-anglican-church-conservative-divides/   Study Shows Evangelicals Don't Know Theology: https://www.christianitytoday.com/2025/10/state-of-theology-evangelicals-confused-conflicted-belief/ Other Resources: Slow Theology: Eight Practices for Resilient Faith in a Turbulent World (A Guide to Deep Faith in Our Busy Modern Lives) by A. J. Swoboda and Nijay K. Gupta: https://a.co/d/iCKFGjf   Holy Post website: https://www.holypost.com/   Holy Post Plus: www.holypost.com/plus   Holy Post Patreon: https://www.patreon.com/holypost   Holy Post Merch Store: https://www.holypost.com/shop   The Holy Post is supported by our listeners. We may earn affiliate commissions through links listed here. As an Amazon Associate, we earn from qualifying purchases.  

It took two chemotherapy regimens, but Luke Mutter survived a rare form of bile duct cancer. A CT scan found a 14cm tumor in his liver. At that time, his care team told him he had cancer, but it could not identify the type of cancer. He was put on a systemic chemotherapy cocktail of folfirinox and oxaplatin, which attempt to kill the tumor. When that didn't work, Luke learned he was a candidate for a hepatic artery infusion, which included chemo far stronger than his first regimen. Luke has achieved survivorship and is very thankful to be to lead a healthy lifestyle. Considering he was eventually diagnosed with bile duct cancer, his journey in an unlikely place. His feet. He saw a doctor thinking that as an active runner, he had plantar fascilitis. Walking was very painful, as was laying down on his stomach. That is what led to a CT scan, revealing a 14cm tumor in his liver. Luke saw an oncologist and was told he had cancer, but the doctor could not identify what type of cancer. Nonetheless, the doctor said Luke needed to go on a regimen of systemic chemotherapy, which would affect his entire body, a regimen that sought to kill the tumor. The cocktail consisted of oxaliplatin and folfirinox. He received a dosage every two weeks for 18 months. The tumor withstood the chemo, and Luke went to another hospital, where he qualified for a surgical procedure to install a hepatic artery infusion pump. It directed chemotherapy just to the liver at a dose 300 times stronger than the systemic chemotherapy. Luke Mutter achieved survivorship and is thrilled to be back at work as a sales consultant. He also considers a major blessing that after chemotherapy he can taste food, resume exercising and the ability to make his family and friends laugh. By way of advice, he said during his journey, as much as he could, he decided to take charge, by controlling his mindset, exercise, diet and sleep, or as he like to call the group his MEDS. Luke also serves as a mentor to those diagnosed with cholangiocarcinoma. Additional Resources: Support Group: The Cholangiocarcinoma Foundation https://www.cholangiocarcinomafoundation.org

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of Five to Thrive Live, our guest, Dr. JJ Dugoua, a doctor of pharmacy and of naturopathic medicine, will share effective natural strategies to reduce chemotherapy-induced nerve pain, or peripheral neuropathy. He will update us on the latest researched strategies and share what he sees working in his clinical practice.Five To Thrive Live is broadcast live Tuesdays at 7PM ET and Music on W4CS Radio – The Cancer Support Network (www.w4cy.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com).Five To Thrive Live Podcast is also available on Talk 4 Media (www.talk4media.com), Talk 4 Podcasting (www.talk4podcasting.com), iHeartRadio, Amazon Music, Pandora, Spotify, Audible, and over 100 other podcast outlets.

Aubrey Masango speaks to Dr Sithembile Ngidi, Clinical & Radiation Oncologist as they discuss the importance of breast cancer awareness, the latest developments in breast cancer research, treatment options, and innovative therapies.Tags: 702, Aubrey Masango show, Aubrey Masango, Breast Cancer Awareness, Dr Sithembile Ngidi, Mammogram, Chemotherapy, Malignant tumor, Biopsy, Breast lumps, Triple negative breast cancer The Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In episode 94 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by osteosarcoma survivor Will DesJean. Tune in as Will shares his cancer story, the setback he experienced this past year, and how he's getting back to what he loves most – friends, fun, and most of all – swimming. For more of Will's story, tune in to episode 32 with his parents, Chris and Stacy DesJean: https://youtu.be/400NoR1ogVM

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this powerful and deeply intimate episode of The Art of We, Krista sits down with visionary movement educator Melissa Michaels to explore the intersection of sexuality, embodiment, and healing—through the lens of Melissa's late-stage ovarian cancer journey. What unfolds is a story of profound transformation, where trauma, loss, and surgery become portals into deeper intimacy, love, physical pleasure and devotion to life force.“The Art Of We” podcast with Krista Van Derveer and guest Melissa Michaels00:00 — Intro00:55 — Melissa's cancer diagnosis story and background06:15 — The ritual of preparing for surgery & calling in community09:46 — The post-surgery declaration12:19 — Intimacy, partnership, and scarred bodies15:34 — How Melissa worked with pain and chemo23:12 — Building intimacy with others & the sacredness of presence25:36 — Chemotherapy: grief, gratitude, and identity shifts28:21 — Reclaiming sexuality and orgasm after cancer33:04 — The long road back to intimacy and physical connection 36:36 — Balancing solitude and partnership with devotion to aliveness40:58 — Melissa's guidance for returning home to your body46:19 — What this journey taught her about love, humanity, and the path forward50:22 — Where to learn more about Melissa's work & the short film Twisted GiftReach out with your thoughts, experiences, and topics you want to hear about. We love hearing from you!Resources Mentioned: Our Top 10 Relationship Agreements Golden BridgeGolden Girls GlobalGet in Touch: The Art Of We WebsiteThe Art of We Instagram Integrative Psychiatry Institute: Psychedelic Therapy TrainingRate, Review & Follow on Apple Podcasts: If you want to show your support for this show, please consider rating and reviewing The Art of We on Apple Podcasts. To do that, open the Apple Podcasts app and search for The Art of We. Scroll to the bottom of the package and rate with 5 stars. Let us know your favorite part of the show by clicking “Write a Review.” While you're at it, follow the show so you can get the latest episode delivered to your phone weekly. Listen to the episode on Apple Podcasts, Spotify, YouTube or on your favorite podcast platform.

I've been to a lot of medical conferences, but veterinary medicine conferences are different. Picture me, a human ophthalmologist, standing in front of a thousand vets, showing them photos of my dog Milo's eyes (because why not?). Turns out, they loved it and then immediately called me out for doing the exact thing they can't stand about human doctors. Oops. Kristin and I also get into the strange overlap between vet medicine and human medicine (yes, the cardiologists still argue), why ER veterinarians might actually have the hardest job in medicine, and how I managed to accidentally do the very thing vets complain about most. And if that's not enough, we dive headfirst into a Twitter firestorm about whether doctors should ever “Google it” in front of patients, plus a surprise crash course in chemotherapy drugs straight from my med school review book. Takeaways: Vet vs. Human Medicine – The personalities are eerily similar… but vets may have the tougher gig. The Milo Moment – How my dog's eyesight became the star of my keynote. Human Doctor Problem – Why vets roll their eyes when we try to flex our “expertise” in their clinics. Googling in the Exam Room – The controversial tweet that sparked a million opinions. Chemotherapy 101 – A chaotic but oddly fascinating attempt to explain cancer drugs on the fly. — To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: https://glaucomflecken.com/glauc-to-me/ If you are interested in buying a book from one of our guests, check them all out here: https://www.amazon.com/shop/dr.glaucomflecken If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: https://anatomywarehouse.com/?aff=14 Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Today's episode is brought to you by DAX Copilot from Microsoft. DAX Copilot is your AI assistant for automating clinical documentation and workflows helping you be more efficient and reduce the administrative burdens that cause us to feel overwhelmed and burnt out. To learn more about how DAX Copilot can help improve healthcare experiences for both you and your patients visit ⁠aka.ms/knockknockhi⁠. Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices

Lung cancer is one of the world's biggest killers. Today, we explore why, and how medical research into this disease is seeing the development of better diagnostic tools, cancer treatments and even a vaccine to prevent tumours from taking hold in the first place... Like this podcast? Please help us by supporting the Naked Scientists

Drs. Liu and Scott review second-line treatments of small cell lung cancer following first-line maintenance treatment, including platinum rechallenge and other post-platinum agents.

"I haven't spent a lot of time breaking down and crying. Every time I've started to have a breakdown, I look at myself in the mirror and say, 'Stop, go about your day.' I know at some point I need to let those tears out, but I don't really have time, so I'm stuffing it all down." I'm fresh off my fifth round of chemotherapy, and am back on the couch recording with friends. This time for chemo (and scan day!), I was again joined by Cousin Jackie, and this is our recap from the day at the infusion center and the few days we spent together.  SPONSOR:  Lagoon: Click here to take Lagoon's 2-minute sleep quiz to see which pillow is right for you. (I'm an Otter!) Use code ALI at checkout for 15% off your next Lagoon order. Oofos: The best in recovery footwear! Check out Oofos's 2025 Project Pink collection, where 10% of every purchase is donated to cancer research.  Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Fr. John Brancich, FSSP, is the pastor of St. Stanislaus Catholic Church in Nashua, New Hampshire. He was ordained into the Priestly Fraternity of Saint Peter in 2004. In Today's Show: What does it mean to be "born-again"? When did Jesus realize he was the son of God? What do I say to my non-Catholic friend who doesn't believe in Mary's virginity? Can priests consecrate grape soda? Is it ok to refuse Chemotherapy? Is it a sin to work on Sundays? Are young children immediately in heaven?  Visit the show page at thestationofthecross.com/askapriest to listen live, check out the weekly lineup, listen to podcasts of past episodes, watch live video, find show resources, sign up for our mailing list of upcoming shows, and submit your question for Father!

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Doctors often use euphemisms to dance around the 'C' word. But for oncologist Dr Ranjana Srivastava, how you talk to someone with cancer goes beyond "shadows, lumps and lesions". It's all about compassion and clarity, even when honesty is difficult.Ranjana Srivastava was a young doctor in regional Australia, accompanying her consultant on his late night rounds when she heard a patient say something that stopped Ranjana in her tracks.It was in that moment that she finally knew what her speciality was going to be: oncology. Ranjana now works in Melbourne as an oncologist and an author.She often writes about the need for clarity and compassion in doctor-patient conversations, to deliver good news, bad news and everything that falls between.Ranjana had her own experience of being at the receiving end of devastating news when she was pregnant with twins.Ranjana has carried the lesson she received from her own doctor forward, into her work as an oncologist, where bearing witness to the attitudes of her patients has changed the way she sees the world and has helped put her own life in perspective.Further informationRanjana's latest book, Every Word Matters, is published by Simon & Schuster.She has published seven books about cancer and end of life care, including A Better Death, Tell Me the Truth, Dying for a Chat, So It's Cancer: Now What, and After Cancer: A Guide to Living Well.Ranjana also writes a regular column for The Guardian.In 2017, Ranjana was awarded an Order of Australia medal for her work as an oncologist and in improving doctor-patient communication.This episode of Conversations was produced by Meggie Morris. Executive producer is Nicola Harrison.It explores cancer, oncology, the big C, cancerland, breast cancer, bowel cancer, how to survive cancer, incurable cancer, end of life care, palliative care, honest doctors, refusing treatment, chemotherapy, radiation, how to be honest with patients, doctor patient relationship, geriatric oncology, India, migration, motherhood, late term miscarriage, pregnancy, writing, books, origin story, journalism.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Check out this highly relevant encore show from August 29, 2025! (1:47) Bible Study: Mk 6:17-29 Father talks about the Herodian family. They were not good people. (18:25) Break 1 (19:40) Letters: Do you need to go through Chemotherapy in order to preserve your life, what is penance really and why is the Catholic 10 commandments different from the Protestant 10 commandments? Father answers all of this questions and more. (35:34) Break 2 (36:11) Word of the Day: Delighted (38:49) Phones: Cathy - call no man your father. Can you explain more? Jennifer - My family rejects Vatican 2. How do I explain this to them? Roe - Can a minister to the homebound bring multiple hosts to someone? Do they really stay consecrated the whole time?

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

I'm fresh off my fourth round of chemotherapy, and am back on the couch recording with friends. This time for chemo, I was joined by my OG running blog friend Emily Halnon, and this is our recap from the day at the infusion center and the few days we spent together.  SPONSOR:  Lagoon: Click here to take Lagoon's 2-minute sleep quiz to see which pillow is right for you. (I'm an Otter!) Use code ALI at checkout for 15% off your next Lagoon order. Follow Ali: Instagram @aliontherun1 Join the Facebook group Support on Patreon Subscribe to the newsletter SUPPORT the Ali on the Run Show! If you're enjoying the show, please subscribe and leave a rating and review on Apple Podcasts. Spread the run love. And if you liked this episode, share it with your friends!